Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity.
View/ Open
Date
2019-03Author
Watts, E
Heidenreich, D
Tucker, E
Raab, M
Strebhardt, K
Chesler, L
Knapp, S
Bellenie, B
Hoelder, S
Type
Journal Article
Metadata
Show full item recordAbstract
Concomitant inhibition of anaplastic lymphoma kinase (ALK) and bromodomain-4 (BRD4) is a potential therapeutic strategy for targeting two key oncogenic drivers that co-segregate in a significant fraction of high-risk neuroblastoma patients, mutation of ALK and amplification of MYCN. Starting from known dual polo-like kinase (PLK)-1-BRD4 inhibitor BI-2536, we employed structure-based design to redesign this series toward compounds with a dual ALK-BRD4 profile. These efforts led to compound ( R)-2-((2-ethoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-7-ethyl-5-methyl-8-((4-methylthiophen-2-yl)methyl)-7,8-dihydropteridin-6(5 H)-one (16k) demonstrating improved ALK activity and significantly reduced PLK-1 activity, while maintaining BRD4 activity and overall kinome selectivity. We demonstrate the compounds' on-target engagement with ALK and BRD4 in cells as well as favorable broad kinase and bromodomain selectivity.
Collections
Subject
Cell Line, Tumor
Humans
Cell Cycle Proteins
Transcription Factors
Antineoplastic Agents
Protein Kinase Inhibitors
Structure-Activity Relationship
Substrate Specificity
Drug Design
Anaplastic Lymphoma Kinase
Research team
Medicinal Chemistry 4 (including Analytical Chemistry)
Paediatric Solid Tumour Biology and Therapeutics
Language
eng
Date accepted
2019-02-21
License start date
2019-03
Citation
Journal of medicinal chemistry, 2019, 62 (5), pp. 2618 - 2637
Publisher
AMER CHEMICAL SOC